S oft-tissue sarcomas are malignant connective tissue lesions of mesenchymal origin that can manifest at any location throughout the body, are challenging to treat, and generally have been associated with poor prognostic outcomes [1] [2] [3] . Soft-tissue sarcomas represent approximately 0.6% of all cancer cases 4 . Various etiological risk factors, such as environmental exposures to various chemicals 5, 6 , viruses 7 , exogenous hormonal influences 8 , increased body-mass index 9 , genetic determinants 10, 11 , and high levels of ionizing radiation [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , have been associated with the development of soft-tissue sarcoma.
Radiation-induced soft-tissue sarcomas may occur as secondary cancers attributed to radiation therapy 12, 14, 15, 24 or Thorotrast (thorium dioxide) induction 13 , with radiation doses from 9 gray (Gy) or higher [16] [17] [18] [19] [20] [21] [22] [23] and variable latency periods 25 . In fact, worse prognostic outcomes have been associated with radiationinduced soft-tissue sarcomas [26] [27] [28] ; however, the role of low to moderately high levels of ionizing radiation exposure on the development of soft-tissue sarcomas is unknown. Until recently, it was a long-held belief that bone sarcomas were induced by very high levels of ionizing radiation exposure (i.e., >10 Gy). However, due to a recent study by Samartzis et al. 29 , which was based on atomic-bomb survivors, the authors concluded that much lower levels of radiation exposure than previously believed may lead to the development of bone sarcomas.
Due to the increase of ionizing radiation exposure in medical and occupational settings as well as a potential risk that may stem from nuclear facility catastrophes (e.g., Chernobyl, Three Mile Island, and Fukushima Daiichi) [30] [31] [32] [33] [34] [35] , as well as those associated with radiation therapy in general and newer, more conformal techniques that tend to increase the amount of normal tissue exposed to low to moderate doses of ionizing radiation, there is a need to understand if these sources of exposure may lead to the development of soft-tissue sarcoma. Therefore, a prospective, longitudinal study was performed to assess the role of low to moderately high levels (i.e., 0 to approximately 3 Gy) of ionizing radiation exposure on the development of soft-tissue sarcomas in the context of the Life Span Study (LSS) cohort of Japanese atomic-bomb survivors of Hiroshima and Nagasaki.
Materials and Methods

Study Design and Population
A prospective, longitudinal study was performed of atomic-bomb survivors (time of exposure: August, 1945) from Hiroshima and Nagasaki, Japan, who were part of the LSS cohort (N = 120,321) of the Radiation Effects Research Foundation (RERF) to assess the development of soft-tissue sarcoma. Characteristics of the LSS cohort have been previously reported 29, [36] [37] [38] [39] [40] [41] [42] . The last update of the LSS was in 2001. This was the case because gathering of data and materials in a systematic and meticulous manner in the prefectures of Hiroshima and Nagasaki took several years to complete. Some information necessitated special arrangement with local medical institutions. Since the tumor registries of Hiroshima and Nagasaki were established on January 1, 1957, and January 1, 1958, respectively, any individuals who were deceased, diagnosed with cancer, or lost to follow-up before January of 1958 were excluded from the study (Fig. 1) . Furthermore, individuals with unknown doses or residencies outside the cities at the time of the bombings were also excluded from the study (Fig. 1) . Colon doses were used as a good approximation to dose for all soft tissue, and were estimated in units of weighted Gy according to the Dosimetry System of 2002 (DSO2), making allowance for biological effectiveness in that neutrons were weighted 10 and gamma 1 43 . Since disease mechanisms may entail systemic effects following whole-body radiation exposure, colon dose has been used to approximate whole-body doses in the LSS cohort, which also facilitates comparisons between disease 39 .
Identification and Clinical Assessment of Sarcomas
Utilizing the Hiroshima and Nagasaki Tumor Registries, primary and malignant soft-tissue sarcomas were identified and further verified on the basis of autopsy reports, death certificate records, and tissue registry information 44 . Diagnosis of soft-tissue sarcoma development was based on initial physician consultation and treatment regarding tumor-related symptoms or diagnosis irrespective of symptoms further verified pathologically. If the tumor was discovered during an autopsy, it was considered as being pathologically diagnosed. Tumors diagnosed outside of the tumor registry catchment area were excluded. The site of origin and histological characteristics of the tumors were identified based on the World Health Organization's International Classification of Diseases for Oncology (ICD-O), 1st to 3rd editions. Age at the time of the bombings, age at sarcoma diagnosis (attained *Subjects with radiation dose <0.005 served as control subjects being exposed to either no or very minimal amounts of radiation equivalent to annual background radiation doses, which facilitated comparisons to subjects with exposure to higher doses.
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age), duration from exposure to sarcoma development, development of metastases, and five-year survival rate were assessed.
Statistical Analysis
Descriptive and frequency analysis was calculated of various subject and radiation parameters as well as for site of origin and histological types of soft-tissue sarcomas.
Rates were computed based on Poisson regression modeling of grouped survival data 45 . Person-years of observation were accumulated from January 1, 1958, to the event of first tumor diagnosis, death, or December 31, 2001 , whichever came first. After implementing appropriate background functions in age and year of birth, various dose-response associations were assessed to determine the best-fitting model (i.e., linear, linear quadratic, quadratic, spline, and threshold) and to assess radiation effects on two scales: the multiplicative excess relative risk (ERR: total rate = [background rate] · [1 1 ERR]) and the additive excess absolute rate (EAR: total rate = background rate 1 EAR). The ERR, which is the standard model used in radiation epidemiology, allows for analysis of the excess radiation-related incidence separately from background incidence. Models were fitted with use of Epicure statistical software (Seattle, Washington) 45 . Effect modification by sex, age at exposure, or age at sarcoma diagnosis was assessed with likelihood ratio tests that made use of log-linear effect-modifier models on each scale. Dose-response models and the ERR-EAR scales were compared with use of the Akaike information criterion (AIC) (the deviance plus twice the number of parameters, including the joint point in the case of the spline model or the threshold in the case of the threshold model) 46, 47 . The best-fitting model was selected on the basis of the lowest value of the AIC. Kaplan-Meier analysis was performed to determine the five-year survival rate. Mann-Whitney U tests were performed to assess two independent samples. All p values were two-sided and significance was declared at p < 0.05, considering the 95% confidence interval (CI) bounds for precision.
Ethics Approval
The conduct of the LSS was approved by the Human Investigation Committee of the RERF. The use of death certificates of the LSS subjects was approved by the Japanese Ministry of Internal Affairs and Communications. The respective committees of the Hiroshima City Cancer Registry, Hiroshima Prefecture Tissue Registry, and Nagasaki Prefecture Cancer Registry approved the use of cancer registry data for the present study.
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Results
T
here were 80,180 individuals who met the inclusion criteria, with a total of 2,170,732 person-years (37% males, 63% females) of observation (Table I) . Of those individuals, 104 softtissue sarcoma cases were identified, which consisted of thirty-six males (34.6%) and sixty-eight females (65.4%). The overall crude incidence associated with soft-tissue sarcomas was 4.8 per 100,000 person-years (4.4 in males, 5.0 in females). The crude baseline (<0.005 Gy exposure) incidence (observed cases/person-years) was 4.1 per 100,000 person-years, similar to the age-and-birth-year-adjusted incidence of 4.4 per 100,000 person-years in that group (Table I) . Twenty-seven cases were confirmed on autopsy and two were confirmed by death certificate. No difference in radiation dose was noted between those cases confirmed on autopsy or death (mean: 0.24 Gy; ± standard deviation [SD]: 0.53 Gy; range: 0 to 2.35 Gy) compared with those diagnosed alternately (mean: 0.16 Gy; ± SD: 0.35 Gy; range: 0 to 1.82 Gy) (p = 0.279).
Among the soft-tissue sarcoma cases, the mean age at the time of the bombings was 26.8 years (± SD: 15.9 years; range: zero to seventy years) and the mean age at diagnosis was 63.6 years (± SD: 14.0 years; range: twenty-six to ninety-three years). The time period from exposure to diagnosis (potential latency period) of the sarcoma was 36.8 years (± SD: 12.5 years, range: fourteen to fifty-six years). The mean colon dose was 0.18 Gy (± SD: 0.40 Gy, range: 0 to 2.35 Gy).
The majority of cases occurred in the uterus (n = 17, 16.3%) and stomach (n = 14, 13.5%) ( Table II) . According to histology, the majority of sarcomas were leiomyosarcomas (n = 37, 35.6%) and malignant fibrous histiocytomas (n = 11, 10.6%) (Table III) . Due to varied site of origin and histology, the authors could not discern with confidence the effects of colon-dose radiation exposure and the development of specific sarcoma types. *NOS = not otherwise specified.
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T 6, 2013 Adjusting for age at diagnosis and year of birth, incidence was higher among exposed persons than among persons with <0.005 Gy exposure, evidencing a trend despite the small numbers of cases and with persons exposed to >0.5 Gy showing observed numbers of cases about double the number expected if there were no radiation effect (Table I) . ERR model comparisons of radiation effect on soft-tissue sarcoma development revealed that a linear dose-response model fit better (AIC = 968.15) than linear-quadratic (AIC = 970.09), quadratic (AIC = 969.43), spline (AIC = 971.85), or threshold (AIC = 969.93) models. The linear ERR, 1.01 per Gy (95% CI: 0.13 to 2.46, p = 0.019), was significant (Fig. 2) . In addition, the risk of sarcoma development significantly increased with increasing year of birth (p = 0.037) and with increasing age at diagnosis (p < 0.001); however, sex was not a strong predictive factor (p > 0.5). With the EAR model, the estimated excess rate per Gy was 4.32 per 100,000 persons per year (95% CI: 1.14 to 8.94, p = 0.001). The ERR and EAR remained significant after excluding persons exposed to 2 Gy or more (ERR 1. The ERR model demonstrated significant radiation effect modification by age of diagnosis (log-linear effect modifier parameter 23.7, 95% CI: 26.4 to 20.8, p = 0.017, AIC = 962.40), but not the EAR model (p > 0.5; for unmodified EAR, AIC = 961.49). Neither sex nor age at exposure significantly modified the ERR marginally (p = 0.38 and p = 0.065, respectively) or after accounting for modification by age of diagnosis (p > 0.5 and p = 0.43, respectively), nor did either factor modify the attained-age-constant EAR (p > 0.5 and p = 0.21, respectively). The log-linear parameter for log age in the unmodified EAR model was 3.4 (95% CI: 2.30 to 4.70), consistent with the attained age modifier of the ERR (23.7).
Based on the last LSS assessment of soft-tissue sarcoma cases, twenty-three individuals were alive (22.1%). Metastases had occurred in forty-six individuals (44.2%) by the time of the last follow-up. The mean survival period after diagnosis was 7.1 years (± SD: 9.1 years; range: zero to fortyfour years). The five-year survival rate was 39%, which did not statistically differ between sex, age at diagnosis, and sarcoma site of origin or histology (p > 0.05). Regression analysis did not note such factors to be significantly predictive in this population. However, individuals in whom metastases developed had a significantly shorter survival period (mean: 3.0; ± SD: 4.0; range: zero to twenty-one years) than did those without metastases (mean: 9.5; ± SD: 8.7; range: zero to thirty-one years) at the time of the last assessment (p < 0.001). The five-year survival rate for individuals in whom metastases developed as compared with those with no metastases was 17.4% and 53.4%, respectively (Fig. 3) . The effects of treatment type on survival rate could not be discerned from this study. *NOS = not otherwise specified. Illustration of various excess relative risk (ERR) dose-response models for colon dose in units of weighted gray (Gy), with a relative weight of 10 for neutrons compared with gamma radiation. Baseline models were adjusted for age at the time of sarcoma diagnosis and year of birth.
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Discussion E xposure to ionizing radiation can lead to tissue damage and genetic mutation, resulting in numerous cancerous or noncancerous diseases 48, 49 . Ionizing radiation exposure has been of paramount public-health concern, further brought to light due to the recent breakdown of the Fukushima Daiichi nuclear power plant in Japan in March of 2011. Although radiation therapy is often utilized to treat cancerous lesions, studies have shown that the use of ionizing radiation modalities (e.g., radiographs, computed tomography scans, fluoroscopy) for diagnostic and as surgical adjuncts continues to rise and that these modalities on many occasions have been utilized quite liberally, increasing radiation exposure to the patient and at times to the health-care practitioner [30] [31] [32] 34, 50 . In fact, the use of ionizing radiation in the medical setting in the United States has increased fourfold from the early 1980s to 2006 51 . The atomic-bomb survivors of Hiroshima and Nagasaki, Japan, are the world's largest and most unique source of information to assess the effects of low to moderately high levels of ionizing radiation on the development of cancer and noncancerous disease. This population was exposed to whole-body ionizing radiation at the time of the bombings in August of 1945 and has been systematically assessed since then for the development of disease as part of the LSS cohort 29, [36] [37] [38] [39] [40] [41] [42] . Approximately 25,000 subjects of this cohort served as ''control subjects,'' having been exposed to either no or very minimal (i.e., <0.005 Gy) amounts of radiation equivalent to annual background radiation doses, which facilitated comparisons to subjects with exposure to higher doses (Fig. 2, Table I ). As such, the LSS cohort of atomic-bomb survivors has broadened the understanding of the effects of ionizing radiation on the development of disease and has contributed to radiation protection guidelines and prevention initiatives.
According to an analysis by Preston et al. 39 , who reported the cancer incidence in atomic-bomb survivors of Hiroshima and Nagasaki in the LSS cohort, sarcomas as a group (bone sarcomas included) exhibited an ERR per Gy of 0.48 (90% CI: 0.07 to 1.4), with an EAR of 0.39 per 10,000 per person-year Gy (90% CI: 0.08 to 1.04) at age seventy years, after exposure at age thirty years, in a linear fashion. However, according to a recent report by Samartzis et al. 29 , bone and soft-tissue sarcomas possess different susceptibilities to ionizing radiation exposure. In fact, Samartzis et al. 29 reported that bone sarcomas present with a linear dose-response model with a threshold at 0.85 Gy and an ERR per Gy of 7.5 (95% CI: 1.34 to 1.85 Gy) in excess of 0.85 Gy.
To our knowledge, our study represents one of the largest and longest prospective evaluations of primary softtissue sarcomas arising in individuals who were exposed to a single whole-body dose of ionizing radiation. Our analyses revealed that soft-tissue sarcomas may be associated with exposure to low to moderately high levels of ionizing radiation, showing a linear dose-response (nonthreshold) model with an ERR of 1.01 per Gy. This linear dose-response model is in line with most other cancers attributed to radiation induction in atomic-bomb survivors of Hiroshima and Nagasaki 39 . Furthermore, negative effect modification of the ERR by attained age and age at exposure is seen with solid cancers overall in the LSS population 39 , but age at exposure Nonadjusted survival analysis of patients with soft-tissue sarcomas stratified by the presence of metastases. The overall five-year survival rate was 39%. Five-year survival rates with or without metastases were 17.4% and 53.4%, respectively.
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T 6, 2013 was only marginally significant in the present analysis. That age at diagnosis was a significant modifier of the ERR-but not the EAR-suggests that the excess rate may be constant with respect to attained age. The most common histological types of soft-tissue sarcoma noted in atomic-bomb survivors were leiomyosarcomas and malignant fibrous histiocytomas, which is also generally similar in other populations 52 . Although there are numerically more women with soft-tissue sarcomas in the study population, the sex distribution of the exposed population essentially matches the sex distribution of individuals with soft-tissue sarcomas in the cohort, indicating no apparent effect of sex on the incidence of sarcoma induction.
Prognostic outcomes of soft-tissue sarcomas are dependent on numerous factors, such as histology, grade, size, location, duration, age of the patient, presence of metastases, treatment modality, surgical margin status, and age. In our study, the survival period was less in those individuals who experienced metastases. Furthermore, the five-year survival rate of all sarcomas was 39% (17.4% in subjects with metastases), which is much lower than that reported in epidemiological studies in which ionizing radiation exposure was not a factor. A recent Surveillance, Epidemiology and End Results (SEER) assessment noted that the five-year survival rate of all soft-tissue sarcomas was approximately 71% 52 . However, studies have shown that radiation-induced sarcomas have worse prognostic outcomes, which may further explain the lower survival rate in our study population [26] [27] [28] . As such, our study further stresses the important clinical impact of radiationinduced soft-tissue sarcomas and the need to prevent their occurrence.
With newer modalities, including intensity-modulated radiation therapy (IMRT), there is some evidence to suggest that the integral dose over the tissue receiving some dose is increased and that a larger volume of tissue adjacent to the target tissue may receive an appreciable dose of radiation [53] [54] [55] . This effect can be attributed to the greater number of beams generally utilized to increase conformality in IMRT, resulting in a greater number of entry and exit points exposed to some dose of radiation therapy. There is also increased leakage from the gantry head and through the multileaf collimator due to the greater number of monitor units required to deliver the specified therapeutic dose 56 . For example, treatment of deep-seated pelvic tumors with the use of higher-energy beams to increase dose at depth for dose escalation 57 and superficial tissue sparing 58, 59 can also be accompanied by an increased exposure of adjacent normal tissue due to the production of secondary neutrons 60, 61 . In this setting, the benefit of an increased ability to sculpt the dose to the desired target tissues and avoid organs at risk in the pelvis (such as the bladder and rectum) with IMRT must be weighed against the potential for increased shortterm and long-term risk to the patient-specifically, the increased risk of induction of secondary malignant tumors, including sarcomas.
Although our study represents the largest and longest longitudinal population-based initiative to assess the association between ionizing radiation exposure and soft-tissue sarcomas, as with any study, there are limitations. Since the risk factors of soft-tissue sarcomas were not well understood at the initiation of the LSS, information such as genetic factors and occupational hazards has not been collected systematically for all subjects. However, due to the inclusion of virtually all radiation-exposed persons in the design of the LSS, such variables are unlikely to be confounded with radiation dose in the cohort, apart from their potential impact on survival in the interim between exposure and initiation of cancer follow-up. However, the authors did attempt to exclude certain sarcomas, such as Kaposi sarcoma (none noted since 1980s), that may have a strong association with viruses and giant-cell tumors that are benign or have a questionable malignant nature.
In conclusion, our study attempts to raise awareness that even moderate levels of ionizing radiation exposurefrom medical imaging, radiation therapy, and environmental exposure-can lead to the development of soft-tissue sarcomas. n 
